Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CYP3A5,CYP3A5, encodes a member of the cytochrome P450 superfamily of enzymes. Additionally we are shipping CYP3A5 Kits (7) and CYP3A5 Proteins (3) and many more products for this protein.
Showing 10 out of 61 products:
Human Polyclonal CYP3A5 Primary Antibody for EIA, WB - ABIN453603
Murray, Pritchard, Melvin, Burke: Cytochrome P450 CYP3A5 in the human anterior pituitary gland. in FEBS letters 1995
pharmacokinetics of once-daily tacrolimus formulation in relation to polymorphisms of the donor cytochrome P450 (show CYP Antibodies) family 3 sub-family A polypeptide 5 (CYP3A5) gene and recipient adenosine triphosphate-binding cassette sub-family B member 1 (ABCB1 (show ABCB1 Antibodies)) gene in 80 consecutive living-donor liver transplant recipients
CYP3A5 (6986A > G) genotype, rather than MDR-1 (show TBC1D9 Antibodies) (2677G > A/T) variant, has an impact on tacrolimus pharmacokinetics
SLCO1B1 (show SLCO1B1 Antibodies) rs113681054, SLCO1B1 (show SLCO1B1 Antibodies)*5 (rs4149056), CYP3A4 (show CYP3A4 Antibodies)*1G (rs2242480), and CYP3A4 (show CYP3A4 Antibodies)*5 (rs776746) polymorphisms had no effect on the PK/PD of ticagrelor in healthy Chinese volunteers
study to determine the impact of CYP3A5 genetic polymorphisms on paclitaxel/carboplatin-induced myelosuppression and neurotoxicity in patients with epithelial ovarian cancer; found that CYP3A5*3*3 was associated with a lower risk of paclitaxel/carboplatin-induced myelosuppression compared with other CYP3A5 genotypes
Liver transplant patients with CYP3A5 polymorphisms required significantly higher doses of tacrolimus to achieve target blood concentrations.
CYP3A5 genetic polymorphisms in Uyghur population.
The results suggest that early post-transplantation bioavailability differences in time to reach tacrolimus therapeutic levels are due to CYP3A5 genotype. This also appears to affect graft rejection and survival.
Individual differences in metabolic clearance of risperidone under the present conditions were not significantly influenced by the genotypes of CYP2D6 (show CYP2D6 Antibodies) or CYP3A5
CYP3A5 and MDR1 (show TBC1D9 Antibodies) polymorphisms may be the main explanation for the differences observed in RUP pharmacokinetics.
that there was association between CYP3A5 FNx01 3 polymorphism and the altered risk of acute lymphoblastic leukemia in children, especially in Caucasian populations
This gene,CYP3A5, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by glucocorticoids and some pharmacological agents. The enzyme metabolizes drugs such as nifedipine and cyclosporine as well as the steroid hormones testosterone, progesterone and androstenedione. This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1. This cluster includes a pseudogene, CYP3A5P1, which is very similar to CYP3A5. This similarity has caused some difficulty in determining whether cloned sequences represent the gene or the pseudogene. Multiple alternatively spliced transcript variants have been identified for this gene.
cytochrome P450 3A5
, aryl hydrocarbon hydroxylase
, cytochrome P450 HLp2
, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 5
, cytochrome P450-PCN3
, flavoprotein-linked monooxygenase
, microsomal monooxygenase
, xenobiotic monooxygenase